Moderna, Inc. Finance Lease, Principal Payments
Moderna, Inc. (MRNA) reported Finance Lease, Principal Payments of $23.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-02-20
- Moderna, Inc. finance lease, principal payments for the quarter ending 2022-12-31 was $61.00M, a 38.64% increase year-over-year.
- Moderna, Inc. finance lease, principal payments for the quarter ending 2022-09-30 was $46.00M, a 35.29% increase year-over-year.
- Moderna, Inc. finance lease, principal payments for the quarter ending 2022-06-30 was $46.00M, a 23.33% decline year-over-year.
- Moderna, Inc. finance lease, principal payments for the quarter ending 2022-03-31 was $31.00M, a 1450.00% increase year-over-year.
- Moderna, Inc. finance lease, principal payments for fiscal 2025 was $23.00M, a 91.67% increase from fiscal 2024.
- Moderna, Inc. finance lease, principal payments for fiscal 2024 was $12.00M, a 95.89% decline from fiscal 2023.
- Moderna, Inc. finance lease, principal payments for fiscal 2023 was $292.00M, a 58.70% increase from fiscal 2022.
- Moderna, Inc. finance lease, principal payments for fiscal 2022 was $184.00M, a 31.43% increase from fiscal 2021.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 12 month | Finance Lease, Principal Payments 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $23.00M 10-K · filed 2026-02-20 | ||||
| 2024-12-31 | $12.00M 10-K · filed 2026-02-20 | ||||
| 2023-12-31 | $292.00M 10-K · filed 2026-02-20 | ||||
| 2022-12-31 | $61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $107.00M derived: sum of 2 quarters · filed 2025-02-21 | $153.00M derived: sum of 3 quarters · filed 2025-02-21 | $184.00M 10-K · filed 2025-02-21 | |
| 2022-09-30 | $46.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $92.00M derived: sum of 2 quarters · filed 2022-11-03 | $123.00M 10-Q · filed 2022-11-03 | $167.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-06-30 | $46.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $77.00M 10-Q · filed 2022-08-03 | $121.00M derived: sum of 3 quarters · filed 2024-02-23 | $155.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2022-03-31 | $31.00M 10-Q · filed 2022-05-04 | $75.00M derived: sum of 2 quarters · filed 2024-02-23 | $109.00M derived: sum of 3 quarters · filed 2024-02-23 | $169.00M derived: sum of 4 quarters · filed 2024-02-23 | |
| 2021-12-31 | $44.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-23 | $78.00M derived: sum of 2 quarters · filed 2024-02-23 | $138.00M derived: sum of 3 quarters · filed 2024-02-23 | $140.00M 10-K · filed 2024-02-23 | |
| 2021-09-30 | $34.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $94.00M derived: sum of 2 quarters · filed 2022-11-03 | $96.00M 10-Q · filed 2022-11-03 | $57.51M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-06-30 | $60.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $62.00M 10-Q · filed 2022-08-03 | $23.50M derived: sum of 3 quarters · filed 2023-02-24 | $55.67M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2021-03-31 | $2.00M 10-Q · filed 2022-05-04 | -$36.49M derived: sum of 2 quarters · filed 2023-02-24 | -$4.33M derived: sum of 3 quarters · filed 2023-02-24 | $9.76M derived: sum of 4 quarters · filed 2023-02-24 | |
| 2020-12-31 | -$38.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-24 | -$6.33M derived: sum of 2 quarters · filed 2023-02-24 | $7.76M derived: sum of 3 quarters · filed 2023-02-24 | $8.00M 10-K · filed 2023-02-24 | $7.52M 10-K · filed 2021-02-26 |
| 2020-09-30 | $32.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $46.25M derived: sum of 2 quarters · filed 2020-10-30 | $46.49M 10-Q · filed 2020-10-30 | $46.49M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-06-30 | $14.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $14.33M 10-Q · filed 2020-08-06 | $14.33M derived: sum of 3 quarters · filed 2021-02-26 | $14.33M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2020-03-31 | $241.00K 10-Q · filed 2020-05-07 | $241.00K derived: sum of 2 quarters · filed 2021-02-26 | $241.00K derived: sum of 3 quarters · filed 2021-02-26 | $5.00K derived: sum of 4 quarters · filed 2021-02-26 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $0.00 derived: sum of 2 quarters · filed 2021-02-26 | -$236.00K derived: sum of 3 quarters · filed 2021-02-26 | $0.00 10-K · filed 2021-02-26 | $971.00K 10-K · filed 2020-02-27 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | -$236.00K derived: sum of 2 quarters · filed 2020-10-30 | $0.00 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | -$236.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $236.00K 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |